The liver steatosis severity and lipid characteristics in primary biliary cholangitis

BMC Gastroenterol. 2021 Oct 22;21(1):395. doi: 10.1186/s12876-021-01974-4.

Abstract

Background: Patients with primary biliary cholangitis (PBC) often have comorbid dyslipidemia, and determining the degree of hepatic steatosis can help predict the risk of cardiovascular events in PBC patients. The aim of our study was to analyze the characteristics of lipid distribution and the degree of hepatic steatosis in PBC.

Methods: We retrospectively analyzed 479 cases of PBC, chronic hepatitis B (CHB), chronic hepatitis C (CHC), non-alcoholic fatty liver disease (NAFLD), and healthy subjects (Normal) diagnosed by liver biopsy or definitive clinical diagnosis. Controlled attenuation parameter (CAP) values were applied to assess the degree of steatosis of the liver, and lipid levels were also compared in the five cohorts.

Results: We found that among the five groups of subjects, the PBC group had the lowest CAP values (P < 0.001), and the high-density lipoprotein cholesterol (HDL-C) level in the PBC group was higher than normal, CHC and CHB group (P = 0.004, P = 0.033, P < 0.001, respectively).In the multivariate linear analysis, only BMI (β = 1.280, P = 0.028), ALP (β = - 0.064, P = 0.012), TBA (β = - 0.126, P = 0.020), TG (β = 12.520, P = 0.000), HDL-C (β = - 11.338, P = 0.001) and LDL-C (β = 7.012, P = 0.002) were independent predictors of CAP.

Conclusions: Among PBC, CHB, CHC, NAFLD and healthy subjects, PBC had the lowest degree of hepatic steatosis and higher HDL-C levels, all of which were found to be protective factors against atherosclerosis and cardiovascular risk and would provide a valuable reference for the risk of developing cardiovascular events in PBC patients.

Keywords: Controlled attenuation parameter; Dyslipidemia; High-density lipoprotein cholesterol; Liver steatosis; Primary biliary cholangitis.

MeSH terms

  • Cholesterol, HDL
  • Humans
  • Liver Cirrhosis, Biliary* / complications
  • Liver Cirrhosis, Biliary* / epidemiology
  • Non-alcoholic Fatty Liver Disease* / complications
  • Non-alcoholic Fatty Liver Disease* / epidemiology
  • Retrospective Studies

Substances

  • Cholesterol, HDL